Hyloris Pharmaceuticals SaEURONEXT: HYL

Hyloris Pharmaceuticals Provides Update on FDA Review of Valacyclovir for Oral Suspension

Feb 19, 2026 at 6:35 AM UTC · Issued by Hyloris Pharmaceuticals SA

19 Feb 2026 07:29 CET

Subscribe

Issuer

HYLORIS PHARMACEUTICALS SA

press-releasehylorisupdate-valacyclovir-oral-solutionen20260219fv.pdf

Source

HYLORIS

Provider

Euronext

Company Name

HYLORIS

ISIN

BE0974363955

Symbol

HYL

Market

Euronext

Earlier from Hyloris Pharmaceuticals Sa

Hyloris Pharmaceuticals: Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdingsFeb 2
Hyloris Pharmaceuticals: Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European MarketsJan 19
Hyloris Pharmaceuticals: Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMedDec 30, 2025
Hyloris Pharmaceuticals: Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSIONDec 29, 2025

All Hyloris Pharmaceuticals Sa news releases